Applicants,Chemical_Name,Funding_requested_for,Pharmaceutical,Schedules,Therapeutic_group
AstraZeneca,Benralizumab,Severe eosinophilic asthma - Widened access (ACT and >300 cells/ul eosinophil count criteria),Benralizumab,Community and Hospital,
